PharmAbcine

Notifications

Back

Notification settings

Back

Post notifications

Be notified when someone leaves a comment or a reply to your post or comment.

Updates and news

Stay ahead of important updates and news from the site.

Alarm
My account Sign out

Sign-in required.

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Olinvacimab
PMC-309
PMC-402
PMC-403

Recruiting Procedure
Careers Guide
Job Openings

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

About Us

Executive Committee
Board of Directors
Scientific Advisory Board
History

Core Technology

Fully Human Antibody Library
Antibody Development
Antibody Engineering

Pipeline

Olinvacimab
PMC-309
PMC-402
PMC-403

For Investors

For Media

Careers

Recruiting Procedure
Careers Guide
Job Openings

Contact

Location
Inquiry
Partnership Request

한국어
English

한국어
English

Core Technology

For Media

Press Release PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors

TitlePharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of

9 Jul 2024 Views 1121

Press Release PharmAbcine’s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

TitlePharmAbcine’s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degen

2 Jul 2024 Views 1182

Press Release PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024

TitlePharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops fro

23 May 2024 Views 1661

Press Release Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

TitlePharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Propri

23 Apr 2024 Views 2055

Media Center

Subscribe to our website to get latest updates (email@exmaple.com)

Confirm

No
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
Title
Author
Time uploaded
Views
Likes

38
News Article
News Article `` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model``...
Manager
14 Jan 2019
Views979
1

37
News Article
News Article ``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2``...
Manager
14 Jan 2019
Views1013
1

36
News Article
News Article Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at 9TH CLINICAL TRIALS INNOVATION PROGRAMME on April 26-27, 2018.
관리자
14 Jan 2019
Views967
0

35
News Article
News Article Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at Asia Pharma R&D Leaders Summit 2018 on April 17-18, 2018.
관리자
14 Jan 2019
Views893
0

34
News Article
News Article Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at BOSTON CEO on May 10th, 2018.
Manager
14 Jan 2019
Views1053
1

33
News Article
News Article PharmAbcine was introduced today in The South China Morning Post-2018 South Korea Business Report.
Manager
14 Jan 2019
Views953
1

32
News Article
News Article PharmAbcine enters collaboration with MSD focused on clinical evaluation of TTAC-0001 in combination with KEYTRUDA® (pembrolizumab) in recurrent glioblastoma and breast cancer.
Manager
14 Jan 2019
Views1119
1

31
News Article
News Article Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at Asia Pharma R&D Leaders Summit 2018 on April 17-18, 2018.
Manager
14 Jan 2019
Views901
1

30
News Article
News Article Dr. Jin-San Yoo, CEO of PharmAbcine is invited to 36th JP Morgan Healthcare Conference.
Manager
14 Jan 2019
Views929
1

29
News Article
News Article Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present PharmAbcine`s R&D progress at Biotech Showcase 2018.
Manager
14 Jan 2019
Views966
1

Previous
10
11
12
13
14
15
16
17
18
Next

About Us
Core Technology
Pipeline
- Olinvacimab
- PMC-309
- PMC-402
- PMC-403
For Investors
For Media
Careers
Contact

LinkedIn I Facebook I YouTube

- 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
  Yuseong-gu, Daejeon, 34047, Republic of Korea
- HQ +82-42-863-2017
- R&D Center +82-42-861-2017
- FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.

2F, Research Building 2, 70,

Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea

HQ +82-42-863-2017

R&D Center +82-42-861-2017

Investor Relations +70-4294-6097

FAX +82-42-863-2080

COPYRIGHT BY PharmAbcine Inc.

ALL RIGHTS RESERVE